Free Trial
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free TNFA Stock Alerts

TNF Pharmaceuticals (TNFA) Competitors

TNF Pharmaceuticals logo
$4.18 +0.10 (+2.45%)
As of 05/22/2026
Compare

TNFA vs. LSTA, CRVO, OTLK, KYNB, and SKYE

Should you buy TNF Pharmaceuticals stock or one of its competitors? MarketBeat compares TNF Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TNF Pharmaceuticals include Lisata Therapeutics (LSTA), CervoMed (CRVO), Oncobiologics (OTLK), Kyntra Bio (KYNB), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does TNF Pharmaceuticals compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Lisata Therapeutics had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Lisata Therapeutics and 0 mentions for TNF Pharmaceuticals. Lisata Therapeutics' average media sentiment score of 1.55 beat TNF Pharmaceuticals' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Lisata Therapeutics Very Positive
TNF Pharmaceuticals Neutral

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TNF Pharmaceuticals' return on equity of -69.21% beat Lisata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lisata TherapeuticsN/A -103.54% -83.08%
TNF Pharmaceuticals N/A -69.21%-33.98%

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 377.71%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than TNF Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Lisata Therapeutics has higher revenue and earnings than TNF Pharmaceuticals. Lisata Therapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lisata Therapeutics$170K168.27-$16.59M-$1.86N/A
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00N/A

Summary

Lisata Therapeutics beats TNF Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to CervoMed?

CervoMed (NASDAQ:CRVO) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

25.2% of CervoMed shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 35.4% of CervoMed shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TNF Pharmaceuticals has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CervoMed$4.01M7.07-$26.97M-$3.28N/A
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00N/A

CervoMed currently has a consensus target price of $22.60, indicating a potential upside of 638.56%. Given CervoMed's stronger consensus rating and higher possible upside, analysts clearly believe CervoMed is more favorable than TNF Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CervoMed
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

TNF Pharmaceuticals has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. TNF Pharmaceuticals' return on equity of -69.21% beat CervoMed's return on equity.

Company Net Margins Return on Equity Return on Assets
CervoMed-672.80% -136.08% -112.62%
TNF Pharmaceuticals N/A -69.21%-33.98%

CervoMed has a beta of -0.63, suggesting that its share price is 163% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market.

In the previous week, CervoMed had 5 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 5 mentions for CervoMed and 0 mentions for TNF Pharmaceuticals. CervoMed's average media sentiment score of 1.27 beat TNF Pharmaceuticals' score of 0.00 indicating that CervoMed is being referred to more favorably in the media.

Company Overall Sentiment
CervoMed Positive
TNF Pharmaceuticals Neutral

Summary

CervoMed beats TNF Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Oncobiologics?

TNF Pharmaceuticals (NASDAQ:TNFA) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, TNF Pharmaceuticals' average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company Overall Sentiment
TNF Pharmaceuticals Neutral
Oncobiologics Neutral

TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Oncobiologics' return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TNF PharmaceuticalsN/A -69.21% -33.98%
Oncobiologics N/A N/A -291.28%

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oncobiologics has a consensus price target of $4.50, indicating a potential upside of 1,352.08%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than TNF Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oncobiologics
1 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

TNF Pharmaceuticals has higher earnings, but lower revenue than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00N/A
Oncobiologics$1.35M27.74-$62.42M-$1.17N/A

Summary

Oncobiologics beats TNF Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Kyntra Bio has a net margin of 2,199.13% compared to TNF Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Kyntra Bio2,199.13% N/A -36.71%
TNF Pharmaceuticals N/A -69.21%-33.98%

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 2.0% of Kyntra Bio shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kyntra Bio has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kyntra Bio$6.44M4.40$183.45M$40.460.17
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00N/A

Kyntra Bio has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

In the previous week, Kyntra Bio's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Kyntra Bio Neutral
TNF Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kyntra Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Kyntra Bio beats TNF Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does TNF Pharmaceuticals compare to Skye Bioscience?

TNF Pharmaceuticals (NASDAQ:TNFA) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

TNF Pharmaceuticals' return on equity of -69.21% beat Skye Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
TNF PharmaceuticalsN/A -69.21% -33.98%
Skye Bioscience N/A -217.27%-162.39%

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Skye Bioscience is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00N/A
Skye BioscienceN/AN/A-$55.92M-$1.44N/A

TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market.

In the previous week, Skye Bioscience had 9 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 9 mentions for Skye Bioscience and 0 mentions for TNF Pharmaceuticals. Skye Bioscience's average media sentiment score of 0.70 beat TNF Pharmaceuticals' score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

Company Overall Sentiment
TNF Pharmaceuticals Neutral
Skye Bioscience Positive

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,081.72%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Skye Bioscience is more favorable than TNF Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Skye Bioscience
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.57

Summary

Skye Bioscience beats TNF Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get TNF Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNFA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNFA vs. The Competition

Export
MetricTNF PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.72M$3.04B$6.46B$12.34B
Dividend YieldN/A1.97%2.76%5.28%
P/E Ratio-0.0217.7921.2225.65
Price / SalesN/A336.21553.9286.28
Price / CashN/A57.7443.4956.67
Price / Book0.015.8610.377.14
Net Income-$23.36M$74.99M$3.57B$335.98M
7 Day Performance7.46%3.11%6.40%4.15%
1 Month Performance8.01%-3.05%3.52%2.54%
1 Year Performance-76.03%34.38%34.02%35.05%

TNF Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNFA
TNF Pharmaceuticals
N/A$4.18
+2.5%		N/A-76.0%$7.72MN/AN/A6
LSTA
Lisata Therapeutics
2.2384 of 5 stars		$3.12
flat		$15.00
+380.8%		+18.9%$28.41M$170KN/A30
CRVO
CervoMed
3.716 of 5 stars		$2.87
-5.6%		$22.60
+687.5%		-63.9%$28.15M$4.01MN/A4
OTLK
Oncobiologics
1.8169 of 5 stars		$0.23
-0.3%		$4.50
+1,870.2%		-80.6%$27.70M$1.35MN/A20
KYNB
Kyntra Bio
1.0264 of 5 stars		$6.80
-0.4%		N/AN/A$27.65M$6.44M0.17570

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TNFA) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel